Three developments from South Korea's medical aesthetics sector this week signal brand-building, clinical standardization, and cross-border channel expansion. Hanmi Science's premium derma brand ADESII completed its first offline pop-up in Seoul's Seongsu district, drawing 1,800 visitors and launching its flagship Black Pearl PDRN Neo Serum. Daewoong Pharmaceutical and DNC Aesthetics held the DEEP Symposium, unveiling a standardized CaHA injection protocol. Huons Group hosted 30 Chinese doctors from Jilin Province for a K-beauty training workshop, deepening ties in China's aesthetic device and injectable market.
ADESII Pop-Up: Brand Awareness Through Offline Experience
Hanmi Science's premium derma cosmetics brand ADESII held its first offline pop-up event 'ADESII in SEONGSU' from May 27 to June 1 at Yeonmujang-gil, Seongsu-dong, Seoul. The event attracted approximately 1,800 domestic and international visitors, signaling strong early interest for a new brand. The pop-up featured a street runway performance under the 'I CAN SEE' concept, which generated social media buzz and boosted brand recognition. Inside the pop-up, a gacha machine event themed around the brand's hero product, Black Pearl PDRN Neo Serum, offered visitors a tactile brand experience. ADESII positions itself as a premium derma cosmetics brand built on the philosophy of Advanced technology, Derma science, and Science (efficacy clinicals). The Black Pearl PDRN Neo Serum is the brand's first product, formulated with Hanmi's proprietary ingredient H-EGTI, collagen water, and black PDRN (sodium DNA). The company claims clinical proof of elasticity and density improvement, plus low-irritation testing on sensitive skin. ADESII plans to launch subsequent lines targeting whitening, wrinkle, and lifting indications.
DEEP Symposium: Standardizing CaHA Injection Protocols
Daewoong Pharmaceutical and DNC Aesthetics held the DEEP Symposium on May 19 at Sofitel Ambassador Seoul, an educational platform for medical professionals. About 200 clinicians attended in person, with online webinars running simultaneously. The symposium's highlight was the release of CAST-Code™, a standardized injection protocol for DNC's CaHA-based collagen booster, Declash CaHA. Declash CaHA is a collagen-stimulating filler that targets both volume restoration and skin quality improvement. It is marketed globally as Facetem in over 30 countries and holds the No. 2 market share in the CaHA filler segment. The symposium featured three sessions: global CaHA trends by Dr. Carmelo Crisafulli, the CAST-Code™ protocol by Dr. Kiwoong Hong, and the 'Collagen Velvet' combination strategy using Nabota (botulinum toxin) and Declash CaHA by Dr. Jisoo Kook. CAST-Code™ stands for CaHA-based, Anatomical approach, Structural improvement, and Natural change, aiming for predictable and consistent outcomes.
Huons Group Hosts Chinese Medical Delegation for K-Beauty Training
Huons Group, through its affiliates Humedix, Huons Meditech, and Huons Biopharma, hosted 30 doctors from public and private hospitals in China's Jilin Province for a K-beauty Advanced Skill Training (KAT) workshop organized by the Seongnam Industrial Promotion Agency. The delegation toured Huons' headquarters and experienced key medical device products. Humedix secured China's second HA filler approval in 2015 and markets the Elravie brand. Huons Meditech has sold over 10,000 units of its DermaShine skin drug injection device in China and recently received approval for a premium 9-pin needle. Huons Biopharma recently obtained Chinese approval for its botulinum toxin product. The workshop aimed to showcase Huons' integrated competitiveness across medical aesthetics, devices, and biopharma, leveraging nearly a decade of experience in the Chinese market.
What buyers should watch
For overseas distributors and clinic buyers, these developments highlight three supply-chain opportunities. First, ADESII's Black Pearl PDRN Neo Serum represents a new Korean derma-cosmetics entry with clinical backing, potentially available for international distribution. Second, DNC's Declash CaHA and the CAST-Code™ protocol offer a standardized, evidence-based approach to collagen-stimulating fillers, which may appeal to clinics seeking predictable results. Third, Huons' expanding China approvals for HA fillers, injection devices, and botulinum toxin signal a growing portfolio that could be replicated in other regulated markets. Monitor these brands for OEM, distribution, or co-marketing partnerships.
Source: Read the original report | Published: June 11, 2026